Meeting
2022 ASCO Annual Meeting
Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.
Authors
Rino S. Seedor
Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA
Rino S. Seedor , Marlana M. Orloff , Erin Sharpe-Mills , Liam Hulse , Reshma Shelat , Ayako Shimada , Inna Chervoneva , Carol L. Shields , Jerry A. Shields , Michael J. Mastrangelo , Takami Sato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Other Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT02068586
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9586)
DOI
10.1200/JCO.2022.40.16_suppl.9586
Abstract #
9586
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results.
First Author: Sophie Piperno-Neumann
Poster
2021 ASCO Annual Meeting
NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).
First Author: Jose Lutzky
Poster
2021 ASCO Annual Meeting
Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.
First Author: Jessica Cecile Hassel
Poster
2021 ASCO Annual Meeting
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
First Author: Hsiang-fong Kao